How to Choose an IVD Manufacturer: An Evidence-Based Guide to Supplier Qualification

16Oct 2026

IVD Manufacturing IVDCDMO Team Comments: 0

Choosing an IVD manufacturer requires a connected assessment of product suitability, regulatory status, quality management, performance evidence, and manufacturing reliability. The most defensible selection is a manufacturer that can substantiate the claims of the exact product being purchased, supply it lawfully in the intended market, and maintain consistent performance throughout its commercial life.

This applies whether the buyer is a diagnostic distributor, clinical laboratory, healthcare procurement organization, or company developing a private-label test. Certificates, sample demonstrations, and competitive quotations each answer only part of the qualification question.

The framework below combines official regulatory and technical sources with practical procurement recommendations. It focuses on commercially supplied human IVD products and contract manufacturing. Requirements depend on the product, jurisdiction, and business model; laboratory-developed and in-house tests require separate analysis. Regulatory references were checked on 13 October 2026. The proposed scorecard and hypothetical example are analytical tools, not regulatory standards or original clinical research.

1. Define the Product Before Comparing IVD Manufacturers

Supplier qualification should start with a written product and market specification. Without it, apparently comparable quotations may describe substantially different products.

Define:

Intended purpose: the analyte or marker, clinical question, and role in screening, diagnosis, monitoring, or another specified application.
Specimens and population: permitted sample types, collection conditions, and intended patient groups.
Users and setting: central laboratory, professional point-of-care environment, or self-testing.
Technology and output: immunoassay, molecular assay, clinical chemistry, or another platform; qualitative, semiquantitative, or quantitative results.
System configuration: instruments, reagents, calibrators, controls, consumables, and software versions used together.
Target markets and supply needs: destination countries, expected demand, service requirements, and minimum remaining shelf life on delivery.

A serum-based assay does not, by itself, establish suitability for fingerstick whole blood. Likewise, instrument compatibility must be assessed for the specific assay configuration rather than inferred from a broad platform description.

Use the manufacturer’s current instructions for use (IFU) as an initial reference, then identify any gaps between its supported claims and your requirements. FDA’s IVD labeling framework illustrates the importance of intended use, specimen handling, limitations, calibration, and performance information in product documentation.1

2. Establish Who Makes the Product and Who Takes Responsibility

An IVD supplier’s commercial identity may differ from the entities responsible for design, production, regulatory documentation, or distribution.

Map these roles before reviewing price:

Role	Qualification question
Entity identified as manufacturer under the applicable framework	Who holds the relevant manufacturer obligations and controls product claims?
Manufacturing site or subcontractor	Where are critical production, assembly, testing, and release activities performed?
Distributor or trading company	What authority and access does it have to the manufacturer’s technical and quality teams?
OEM, ODM, or CDMO partner	Which development, transfer, production, and lifecycle activities are included in the contract?

OEM, ODM, and CDMO are business descriptions. Do not assume that using one of these labels determines regulatory responsibility.

Request an entity-and-site map connecting the quotation, product label, quality certificates, relevant regulatory records, and critical subcontractors. A manufacturer need not perform every activity internally, but its outsourcing arrangements should be transparent enough to support qualification.

Assess the documented responsibilities and capabilities of each party, including how the buyer can escalate a technical complaint beyond the sales contact.

3. Verify the Quality System and Its Scope

ISO 13485 provides a medical-device quality management framework. A current certificate can support supplier qualification, but it does not establish that every product in a company’s catalog is authorized for sale or suitable for a particular clinical application.2

When assessing an ISO 13485-certified IVD manufacturer, check:

The legal entity and manufacturing locations covered.
Whether the scope covers the relevant product category and activities.
Whether design and development are included when needed for the project.
Certificate validity, issuer, and current status.
Whether the certification body’s accreditation covers the relevant certification activity, where applicable.

Verify the certificate with its issuer or an appropriate verification service. Follow document review with evidence of implementation: relevant audit findings, corrective actions, complaint handling, supplier controls, and product-release records. Access can be managed through confidentiality agreements or controlled review.

Account for the Current FDA QMSR

For manufacturers subject to the US requirements, FDA’s Quality Management System Regulation (QMSR) became effective on 2 February 2026. It incorporates ISO 13485:2016 by reference while retaining applicable FDA requirements.3

FDA also states that it does not require an ISO 13485 certificate of conformance and that possessing one does not exempt a manufacturer from FDA inspection.4

Ask how the supplier demonstrates compliance with the requirements applicable to the product and activities being assessed. A certification document and a functioning quality system are related evidence, but they answer different questions.

4. Confirm Regulatory Status for the Exact Product and Market

Create a regulatory matrix for each shortlisted product. Record its legal manufacturer, model or catalog number, intended purpose, classification, destination market, applicable route, and supporting documents.

United States: Registration Does Not Establish Market Authorization

FDA establishment registration and device listing do not mean that a facility or device is approved, cleared, or authorized. FDA does not issue registration certificates to medical-device facilities.5

For the exact IVD, establish the applicable pathway and verify the relevant records: for example, 510(k) clearance, a granted De Novo request, PMA approval, or a documented basis for an applicable exemption. Match the intended use and device configuration to the evidence presented. FDA describes these routes in its IVD regulatory overview.6

Where an emergency authorization is relevant, check its current status and conditions separately. A pending application is not equivalent to a completed authorization.

European Union: Examine the Basis for CE Marking

For products assessed under the IVDR, review the EU declaration of conformity, classification rationale, and notified-body certificates where required. Classes B, C, and D require notified-body involvement; class A non-sterile devices generally use manufacturer self-declaration, while class A sterile devices require notified-body involvement for the relevant sterility aspects.7

Check the notified body’s designation and scope through the European Commission’s NANDO information system. Verify the authenticity, status, and scope of the certificate itself with the issuing body or applicable official records.8

For legacy products supplied under transitional provisions, request documented eligibility and evidence that applicable conditions and deadlines have been met. An old IVDD document alone is insufficient to establish continued eligibility. The Commission identifies conditions involving continued conformity, significant changes, quality systems, and notified-body applications and agreements.9

Other Markets and WHO Prequalification

Confirm destination-country requirements separately. If WHO prequalification is relevant to the product category or tender, verify the specific product and manufacturing site in the current listing. WHO explicitly distinguishes prequalification from national regulatory approval; absence from the list does not, by itself, establish poor quality.10

Regulatory qualification should establish the lawful basis for the proposed supply arrangement, rather than count how many logos appear in a brochure.

5. Evaluate the Evidence Behind Diagnostic Performance Claims

A diagnostic test manufacturer should be able to connect each material claim to a defined method, relevant samples, acceptance criteria, results, and limitations.

For EU IVD performance evaluation, MDCG 2022-2 explains three connected elements:

Scientific validity: evidence linking the analyte or marker to the relevant physiological state or clinical condition.
Analytical performance: evidence that the device can detect or measure the intended analyte.
Clinical performance: evidence supporting the relationship between test results and the relevant clinical condition or state in the intended context.11

The evidence needed depends on the device and claim. A published biomarker association does not independently validate every commercial assay that measures that biomarker.

Review Analytical Performance at the Relevant Decision Points

Use a product-specific review matrix. The following questions are a practical starting point; not every characteristic applies to every IVD.

Area	Questions for the manufacturer
Precision	How does variability change across concentrations, days, operators, instruments, and reagent lots?
Detection and quantification	What supports the claimed detection limit and, for applicable quantitative assays, quantification limit?
Measuring interval and bias	What happens across the claimed range and around clinically relevant decision concentrations?
Interference and cross-reactivity	Were plausible specimen-related and assay-specific sources of error challenged?
Calibration	How are assigned values established, maintained, and traced to suitable references where available?
Specimen and system compatibility	Which sample types, collection devices, instruments, and software versions were evaluated?

For quantitative assays, do not accept a correlation coefficient as sufficient evidence of agreement. As a mathematical illustration, a method that always reports 20% above another can still correlate perfectly with it. Review bias and its uncertainty at relevant concentrations. CLSI EP09 addresses measurement-procedure comparison and bias estimation using patient samples.12

Examine Clinical Study Design and Statistical Uncertainty

Request the study protocol and report, including population, specimen selection, comparator, sample-size rationale, exclusions, invalid results, and confidence intervals. Determine whether the evaluated users, settings, and product version match the proposed application.

FDA recommends distinguishing diagnostic sensitivity and specificity from positive and negative percent agreement when the comparator is not a reference standard. High agreement can occur even when both methods make errors. Confidence intervals help show uncertainty that a headline percentage conceals.13

Ask for unfavorable findings and their investigation as well as successful results. Assess whether conclusions extend beyond the study population or tested conditions.

Independent studies can strengthen an assessment when their methods and product versions are relevant. However, publication alone does not establish transferability to your application. Unpublished manufacturer reports can also be informative when sufficiently detailed, traceable, and available for competent review.

An Illustrative Example: Why Specificity Matters in Screening

Assume a hypothetical test has 95% sensitivity and 98% specificity in 10,000 people, of whom 1% have the target condition, with no invalid results.

Of 100 affected people, 95 would be expected to test positive.
Of 9,900 unaffected people, 198 would be expected to test positive.
The resulting positive predictive value is approximately 32.4%: 95 ÷ (95 + 198).

These are illustrative expected counts, not observed product data. They show why a procurement team must consider the intended population and testing pathway alongside headline performance figures. The calculation alone does not determine whether a test is appropriate for its intended role.

6. Test Manufacturing Consistency, Stability, and Change Control

Product qualification must connect development evidence with routine commercial production.

As a practical audit exercise, select a released lot and ask the manufacturer to trace its critical materials, production records, in-process results, deviations, final testing, and release decision. Then examine how a rejected lot or a significant complaint was investigated.

Questions worth pursuing include:

Which critical materials are sourced externally, and how are supplier or material changes evaluated?
Can release testing detect meaningful deterioration near an assay cutoff or other critical performance boundary?
How are trends across lots reviewed, rather than merely classifying each lot as pass or fail?
Can the manufacturer identify affected customers if a component problem is discovered later?

WHO’s technical guidance includes specific resources on quality-control panels, test-method validation, and product quality control. These provide useful reference points, particularly for products seeking WHO prequalification.14

Check Stability Under the Actual Supply Conditions

For IVD reagent manufacturers, request evidence covering the applicable shelf life, transport conditions, and in-use or onboard stability. Distinguish stability after opening or reconstitution from unopened shelf life.

WHO’s stability guidance emphasizes real-time evidence and the limitations of accelerated studies. Where accelerated data support an interim claim, examine the scientific justification and the plan for confirmation with real-time results within the relevant regulatory framework.15

For your purchasing decision, compare the validated conditions with the proposed shipping route, storage capacity, and likely rate of consumption. Specify the minimum remaining shelf life at receipt. A long stated shelf life may have little commercial value if most of it has elapsed before delivery.

Evaluate the Response to Changes

Ask how changes to critical reagents, manufacturing sites, processes, instruments, or result-generating software trigger risk assessment, verification or validation, regulatory evaluation, and customer communication.

The qualification objective is to understand how the manufacturer will preserve supported performance when its supply chain or production process changes.

7. Add Development and Data Rights to OEM and CDMO Assessments

For an IVD OEM manufacturer or IVD CDMO, review the proposed development process as carefully as the production line.

Agree on measurable deliverables for feasibility, design inputs, assay optimization, verification, validation, transfer, and scale-up. Distinguish an exploratory prototype from a product ready for commercial release.

The contract should address:

Ownership or licensing of designs, formulations, software, tooling, and project-generated data.
Access to documentation needed for submissions, technical review, investigations, and future changes.
Responsibilities for risk management, performance studies, release, and post-market activities.
Rules for subcontracting, material substitution, and changes affecting agreed specifications.
Transfer assistance and continued access to necessary information if the relationship ends.

Private-label arrangements also need an explicit assessment of labeling and manufacturer responsibilities in each intended market. Changing the brand is a commercial decision with potential regulatory consequences.

8. Compare Total Cost per Reportable Result

Unit price is useful only after essential quality, performance, and regulatory conditions are satisfied.

For laboratory procurement, compare total operating cost against expected reportable results. Include reagents, controls, calibrators, consumables, service, labor, repeat testing, wastage, and expiry. Use the same workload and accounting assumptions for every candidate.

For distribution or contract-manufacturing projects, also compare dossier access, transfer costs, minimum order quantities, inventory commitments, local support, and continuity arrangements.

Ask for evidence of achievable capacity and delivery performance at the relevant site. For instrument-based systems, evaluate service coverage, spare parts, maintenance response, and support for the installed software version.

Avoid converting a supplier’s nominal production capacity into an assumption about the quantity it can reliably deliver to your project.

9. Use a Scorecard After Applying Mandatory Gates

A weighted scorecard can make procurement decisions more transparent. It should be used only after mandatory requirements have been addressed.

For commercial procurement, these gates should include a verified lawful supply route, product suitability, acceptable performance evidence, and resolution of critical quality or safety concerns. For development procurement, evaluate the credibility of the regulatory and evidence-generation plan separately from readiness for commercial supply.

The following is an illustrative buyer-defined model, not a validated industry standard:

Evaluation domain	Suggested weight
Product performance and evidence quality	25%
Regulatory suitability and documentation	20%
Quality system and audit findings	20%
Manufacturing consistency and stability	15%
Supply continuity and service capability	10%
Total cost	5%
Contract terms, data access, and change control	5%
Total	100%

Define scoring anchors before comparing suppliers. Record the evidence, uncertainty, owner, and required follow-up for each score. Adjust weights to the project’s risks; a custom development program may require more emphasis on technical transfer and intellectual property.

An attractive total cannot override a failed mandatory condition. Missing evidence should remain an unresolved qualification item rather than be converted into an optimistic assumption.

10. Qualify Through Documents, Samples, and Audits

A practical sequence is:

Screen documents: request the entity-and-site map, relevant certificates, regulatory evidence, IFU, and performance summaries.
Review technical evidence: examine detailed reports through appropriate confidentiality and data-protection arrangements.
Evaluate representative product: use commercial or appropriately characterized pilot lots, a predefined protocol, and acceptance criteria relevant to the project.
Audit critical activities: use a risk-based onsite or remote assessment, with onsite follow-up where remote evidence is insufficient.
Close gaps and contract: document acceptance decisions, quality responsibilities, change notifications, escalation, and supply commitments.
Monitor after approval: track lot acceptance, complaints, delivery, significant changes, and the need for requalification.

A small sample exercise can inform a purchasing decision, but it cannot independently establish every manufacturer claim or replace required validation. For clinical laboratories, manufacturer qualification also does not eliminate the laboratory’s own applicable verification, validation, and authorization obligations.

Plan evaluations involving human specimens around applicable ethics, specimen-governance, and data-protection requirements. Agree on access to appropriately protected evidence rather than assuming that a supplier can disclose identifiable patient data.

Warning Signs That Require Investigation

Pause qualification when the supplier cannot resolve issues such as:

A certificate that cannot be verified or covers a different entity, site, or activity.
An authorization for a different product configuration or intended use.
Performance percentages without denominators, study methods, or relevant limitations.
Unexplained differences between evaluation samples and commercial production.
Unsupported shelf-life claims or unclear handling of transport excursions.
Restricted technical access that prevents a meaningful assessment even under reasonable confidentiality controls.
Unclear responsibility for complaints, critical changes, or corrective action.

Also investigate promotion of research-use-only products as ready for routine diagnostic use. FDA distinguishes RUO and IUO products from products marketed for established clinical diagnostic use; an RUO label does not establish clinical market authorization.16

A historical recall or inspection finding should be assessed in context: significance, affected products, corrective action, recurrence, and current status. Conversely, an absence of publicly identified findings does not demonstrate that an independent audit has been passed.

Frequently Asked Questions About IVD Manufacturers

What documents should I request from an IVD manufacturer first?

Start with the product specification and IFU, manufacturer and site identities, relevant quality certificates, destination-market regulatory evidence, and performance and stability summaries. Request detailed reports as the candidate progresses through qualification.

Is ISO 13485 enough to qualify an IVD manufacturer?

No. It addresses the quality management system. Product suitability, regulatory status, performance evidence, manufacturing consistency, and supply capability still require separate assessment.2

Does FDA registration mean a diagnostic product is approved?

No. Registration and listing do not establish product approval, clearance, or authorization. Verify the exact product’s applicable pathway and status.5

How should I assess overseas IVD manufacturers?

Apply the same evidence-based criteria to manufacturers in China and other countries. Assess the specific entity, site, and product, then account for destination-market responsibilities, language, logistics, and local service. Country of origin alone is not a sufficient qualification criterion.

How many samples are enough for supplier qualification?

There is no universal sample number for all IVDs. The evaluation plan should reflect its purpose, product risks, required precision, relevant concentrations or subgroups, and applicable requirements. A purchasing pilot and a study intended to establish clinical performance have different objectives.

Selecting an IVD Manufacturer for a Sustainable Partnership

An effective IVD manufacturer selection process produces a documented chain from intended purpose to product claims, supporting evidence, lawful supply, and repeatable production. It also establishes what will happen when a lot fails, a material changes, demand increases, or a field complaint raises a new question.

The strongest candidate is the IVD product manufacturer whose evidence and operating arrangements support your defined application, with uncertainties made explicit and responsibilities agreed before commercial commitment.

References

Official regulatory and standards sources were prioritized. The procurement workflow, evaluation questions, and suggested scorecard are editorial recommendations informed by these sources; they are not themselves legal requirements.

Author Profile

IVDCDMO Team: Written by the IVDCDMO technical and regulatory team, with expertise in diagnostic assay development, GMP manufacturing, ISO 13485 systems, and global IVD commercialization for biotech innovators worldwide.